BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland.
Adequate balance sheet and overvalued.
Share Price & News
How has BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BML has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BML exceeded the Polish Biotechs industry which returned -13.3% over the past year.
Return vs Market: BML exceeded the Polish Market which returned -7.6% over the past year.
Price Volatility Vs. Market
How volatile is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StHow Should Investors React To BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) CEO Pay?
1 month ago | Simply Wall StIntroducing BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML), The Stock That Slid 65% In The Last Five Years
2 months ago | Simply Wall StCould The BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Ownership Structure Tell Us Something Useful?
Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: BML (PLN1.09) is trading above our estimate of fair value (PLN0.33)
Significantly Below Fair Value: BML is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BML is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: BML is unprofitable, so we can't compare its PE Ratio to the Polish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BML's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BML is good value based on its PB Ratio (2.2x) compared to the PL Biotechs industry average (2.5x).
How is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BML is currently unprofitable.
Growing Profit Margin: BML is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BML is unprofitable, and losses have increased over the past 5 years at a rate of -8.8% per year.
Accelerating Growth: Unable to compare BML's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BML is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: BML has a negative Return on Equity (-93.73%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's financial position?
Financial Position Analysis
Short Term Liabilities: BML's short term assets (PLN15.4M) do not cover its short term liabilities (PLN21.0M).
Long Term Liabilities: BML's short term assets (PLN15.4M) do not cover its long term liabilities (PLN31.0M).
Debt to Equity History and Analysis
Debt Level: BML's debt to equity ratio (22.3%) is considered satisfactory.
Reducing Debt: BML's debt to equity ratio has reduced from 28.7% to 22.3% over the past 5 years.
Inventory Level: BML has a high level of physical assets or inventory.
Debt Coverage by Assets: BML's debt is covered by short term assets (assets are 2.2x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BML has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BML is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 30.6% per year.
What is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate BML's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BML's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BML's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BML's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BML's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.
How experienced are the management team and are they aligned to shareholders interests?
Marcin Piróg 0
Mr. Marcin Piotr Piróg serves as Chief Executive Officer and President of Management Board of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek Spólka Akcyjna. Mr. Piróg served as the President of LOT Polish A ...
CEO Compensation Analysis
Compensation vs Market: Marcin's total compensation ($USD76.61K) is below average for companies of similar size in the Polish market ($USD157.18K).
Compensation vs Earnings: Marcin's compensation has increased whilst the company is unprofitable.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s company bio, employee growth, exchange listings and data sources
- Name: BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.
- Ticker: BML
- Exchange: WSE
- Founded: 1944
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: zł68.798m
- Shares outstanding: 62.26m
- Website: https://biomedlublin.com
- BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.
- ul. Uniwersytecka 10
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BML||WSE (Warsaw Stock Exchange)||Yes||Common Bearer Shares||PL||PLN||Jul 2011|
|0RKM||LSE (London Stock Exchange)||Yes||Common Bearer Shares||GB||PLN||Jul 2011|
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company’s prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50, a product used in treating superficial (non-muscle invasive) bladder tumour; GAMMA anty HBs 200 and Gamma anty-HBs 1000 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerol is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma. In addition, the company provides reagents, such as horse serum, bovine serum, calf serum, trypsin, PBS fluid, hanks fluid, parker’s fluid, Eagle 1959 medium, RPMI 1640 medium, and Ogawa medium, as well as pseudo cholinesterase, Ox fibrinogen, and rabbit complements. The company was founded in 1944 and is based in Lublin, Poland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/15 22:34|
|End of Day Share Price||2020/02/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.